Article Text

Download PDFPDF
Risk factors for early onset acute kidney injury after allogeneic haematopoietic stem cell transplantation and the role of drug–drug interactions
  1. Ayşe Günay1,
  2. Ali Ünal2,
  3. Eren Demirpolat3,
  4. Emel Duran4,
  5. Mükerrem Betül Yerer3
  1. 1Faculty of Pharmacy, Clinical Pharmacy Department, Erciyes University, Kayseri, Turkey
  2. 2Faculty of Medicine, Hematology Department, Erciyes University, Kayseri, Turkey
  3. 3Faculty of Pharmacy, Pharmacology Department, Erciyes University, Kayseri, Turkey
  4. 4Faculty of Medicine, Department of Internal Medicine, Division of Intensive Care Unit, Erciyes University, Kayseri, Turkey
  1. Correspondence to Dr Ayşe Günay, Faculty of Pharmacy, Clinical Pharmacy Department, Erciyes University, Kayseri, Turkey; gunayayse{at}yahoo.com

Abstract

Introduction Acute kidney injury (AKI) is an important and life-threatening complication following allogeneic haematopoietic stem cell transplantation (allo-HSCT). This is therefore an active research area with studies aiming to understand the factors that cause this complication.

Materials and methods We conducted a retrospective study to identify the factors that caused AKI in 100 patients who underwent allo-HSCT in the first 100 days after transplantation using logistic regression analysis.

Results The mean time of onset of AKI was 45.58 days (range 13–97) and the mean±SD maximum serum creatinine value was 1.53±0.78 mg/dL. In 47 patients, level 1 or higher AKI occurred in the first month of transplantation and 38 of these patients were diagnosed with a higher level of AKI 31–100 days after transplantation. According to multivariate analysis, use of cyclophosphamide (adjusted odds ratio (AOR) 4.01, p=0.012), mean ciclosporin blood levels ≥250 ng/mL (AOR 2.81, p=0.022) and ciclosporin blood levels ≥450 ng/mL in the first month of transplantation (AOR 3.30, p=0.007) were found to be potential factors for early onset AKI. Ciclosporin blood levels exceeded 450 ng/mL in 35% of those using posaconazole and voriconazole during administration route change of ciclosporin. Use of ≥2 nephrotoxic anti-infective drugs (AOR 3, p=0.026) and developing AKI in the first month of transplantation (AOR 4.14, p=0.002) were found to be potential factors in the development of advanced AKI.

Conclusion Nephrotoxic drugs, cyclophosphamide use and ciclosporin blood levels are factors to be considered to prevent the development of AKI in patients undergoing allo-HSCT.

  • acute kidney injury
  • hematology
  • drug monitoring
  • transplantation
  • nephrology

Data availability statement

No data are available. The data that support the findings of this study are available on request from the corresponding author Ayşe Günay. The data are not publicly available due to research participant privacy.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

No data are available. The data that support the findings of this study are available on request from the corresponding author Ayşe Günay. The data are not publicly available due to research participant privacy.

View Full Text